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Recent reports show that ER stress plays an important role in diabetic retinopathy (DR), but ER stress is a complicated process
involvinganetworkofsignalingpathwaysandhundredsoffactors,WhatfactorsinvolvedinDRarenotyetunderstood.Weselected
89 ER stress factors from more than 200, A rat diabetes model was established by intraperitoneal injection of streptozotocin (STZ).
The expression of 89 ER stress-related factors was found in the retinas of diabetic rats, at both 1- and 3-months after development
of diabetes, by quantitative real-time polymerase chain reaction arrays. There were signiﬁcant changes in expression levels of 13
and 12 ER stress-related factors in the diabetic rat retinas in the ﬁrst and third month after the development of diabetes, Based
on the array results, homocysteine- inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1(HERP),
and synoviolin(HRD1) were studied further by immunoﬂuorescence and Western blot. Immunoﬂuorescence and Western blot
analyses showed that the expression of HERP was reduced in the retinas of diabetic rats in ﬁrst and third month. The expression
of Hrd1 did not change signiﬁcantly in the retinas of diabetic rats in the ﬁrst month but was reduced in the third month.
1.Introduction
Diabetic retinopathy (DR) is one of the severe complications
of diabetes leading to loss of vision. Although the pathogenic
mechanism of DR has been investigated for many years and
a number of theories have been proposed [1, 2], the mecha-
nismofDRremainsunknownandneedsfurtherexploration.
SomediabeticpatientsaresusceptibletoDR,whileothers
are quite resistant or develop minimal pathological changes
[3]. It may be supposed that such DR-resistant patients are
protected genetically. The existence of a DR-resistant gene
was proposed, and a comparative study was performed of
the gene expression between susceptible and resistant DR
patients [4]. It was found that many endoplasmic reticulum
(ER) stress-related factors are highly expressed in non-DR
diabetic patients.
In our earlier work, we found that P58IPK/DNAJC3,
an ER stress-related factor, binds to the ER transmem-
brane protein PERK (protein kinase RNA-activated- (PKR-)
like ER kinase), which is normally activated by the ER
stress/unfolded protein response. By binding to PERK,
P58IPK thereby inhibits its phosphorylation of the α-subunit
ofeukaryotictranslationinitiationfactor2(eIF-2α)andth us
compromises eIF2/EIF2S3’s mediator role in the translation
of mRNA [5]. In this way, P58IPK inhibits ER stress
in the endothelial cells of human retinal vessels. P58IPK
also downregulates the expression of vascular endothelial
growth factor (VEGF), which is associated with regulation
of the pathology of DR [6]. VEGF plays a key role in
DR [7, 8] and is regulated at the transcriptional level by
the unfolded protein response pathway [9]. Recent reports
also show that ER stress plays an important role in DR
[10, 11]. Li et al. [12] demonstrated that multiple ER
stress markers, including 78kDa glucose-regulated protein
(GRP78), phosphoinositol-requiring transmembrane kinase
(IRE)1α, and phosphor-eIF2α were signiﬁcantly upregulated
in the retinas of animal models of type 1 diabetes and
oxygen-induced retinopathy. Our recent work suggests that
early progression of DR may be mediated by ER stress, but
probablydoes not involve changesin activatingtranscription2 Experimental Diabetes Research
factor (ATF)4 or GRP78 [13]. Together, these studies suggest
thatalthoughERstressisinvolvedinthedevelopmentofDR,
its speciﬁc pathogenesis is not yet understood.
ER stress is a complicated process involving a network
of signaling pathways and hundreds of factors that function
by triggering the PERK, IRE1 and ATF6 signaling pathways
[14–16]. In order to delve into the eﬀects of these ER stress-
related factors on DR, we classiﬁed them into 11 categories
according to function (Figure 1, Table 3), based on Jonikas
et al. [17]. We selected 89 ER stress factors from more than
200, based on our work and that of others (Table 4)[ 13, 17–
21]. These factors contain the 11 categories of ER stress.
Expression of these factors in the retinas of diabetic rats was
determinedbyquantitativereal-timePCR(Q-PCR)arraysto
ﬁnd the speciﬁc factors and the ER stress signaling pathways
that may play a key role in the pathogenesis of DR.
2. Methods
2.1.DiabeticRatModel. Two-month-oldmaleSpragueDaw-
ley rats weighing 150 to 200g were obtained from the animal
center of Huazhong University of Science and Technology.
Care, use, and treatment of animals were approved by the
laboratory animal center of Huazhong University of Science
and Technology. Rats were randomly divided into diabetic
and control groups (n = 30 per group). The diabetic model
was created by intraperitoneal injection of a single dose
of streptozotocin (STZ; 65mg/kg in 0.01M citrate buﬀer,
pH 4.5) [22]. Nondiabetic rats (the control group) were
injected with citrate buﬀer only. Fasting plasma glucose
was examined 3d after STZ injection, and diabetes was
conﬁrmedbyavalue ≥16.7mmol/LusingTouchGlucometer
(Boehringer Mannheim Diagnostics, Indianapolis, IN). Our
previous work [13] and that of others [23] have established
thatintheSTZ-induceddiabetesmodel,diabeticretinopathy
develops within one month of the development of diabetes.
Accordingly, one and three months after the STZ injection,
the retinas were separated from the eyes of both the diabetic
and control groups. RNA was extracted and assessed using
Q-PCR arrays, with 9 rats in each group.
2.2. Quantitative Real-Time RNA Polymerase Chain Reaction
(Q-PCR) Arrays. T h em R N Al e v e l so f9 6f a c t o r s( 8 9E R
stress-relatedfactorsand7qualitycontrolfactors)weremea-
sured using Q-PCR arrays. Total RNA was extracted from
rat retinal tissue using Trizol reagent (Invitrogen, Carlsbad,
USA) according to the manufacturer’s instructions. RNA
was treated with DNAase (Invitrogen, Carlsbad, USA) and
puriﬁed using Rneasy MinElute Clean-up Kit (Quiagen,
Hilden, Germany). The cDNA was then synthesized using a
SuperScript III kit (Invitrogen, Carlsbad, USA). Removing
the plate seal from the PCR Array (SABioscience, Frederick,
USA) and adding the cocktails to the PCR Array, Q-PCR was
performed by using the Hot Star polymerase kit (Qiagen,
Venlo, The Netherlands) with SYBR Green technology (ABI,
Tampa, FL). PCR reaction buﬀer was added to a 384-well
PCR array plate which was then tightly sealed with an optical
adhesive cover. The thermocycling program consisted of
95◦C for 10min, then 40 cycles at 95◦C for 15s, and 60◦C
for one minute, then compared the diﬀerential expression of
gene between the two groups.
2.3. Immunoﬂuorescence. Immunoﬂuorescence was per-
formed on 5μm frozen sections. Brieﬂy, retinal sections
were incubated with a rabbit anti-HERP (Santa Cruz
Biotechnology,SantaCruz,Calif)oranti-Hrd1(Biosynthesis
Biotechnology, Beijing, China) antibody (1:200) at 4◦C
overnight. This was followed by the secondary antibody,
ﬂuorescein-conjugated goat antirabbit IgG (Antigene, Wu
Han, China), for one hour. The slides were visualized and
photographed under a ﬂuorescence microscope (Olympus,
Hamburg, Germany).
2.4.WesternBlot. Totalproteinwasextractedfromratretinal
tissue in 300μLl y s i sb u ﬀe r( 5 0 m MT r i sp H7 . 5 ,0 . 5 M
NaCl, 1% NP-40, 1% sodium deoxycholate monohydrate,
2mMEDTA,and0.1%SDS).Aftercentrifugationat1000×g
for 3min, protein extracts were diluted with sample buﬀer
(126mM Tris HCl pH 6.8, containing 20% glycerol, 4% SDS,
0.005% bromophenol blue, and 5% 2-mercaptoethanol)
at a 1:1 ratio and boiled for 3 minutes. The samples
were fractionated according to size on a 12.5% SDS-poly-
acrylamide gel, transferred to a nitrocellulose membrane
(Millipore,Billerica,Mass),andprobedwithpolyclonalanti-
HERP (Santa Cruz Biotechnology, Santa Cruz, Calif) or
polyclonal anti-Hrd1 (Biosynthesis Biotechnology, Beijing,
China)antibodies.Asecondaryantibody,goatantirabbitIgG
(BiosynthesisBiotechnology,Beijing,China)diluted1:1000,
was applied, and the chemiluminescent signal was detected.
T h es a m em e m b r a n ew a sr e u s e dt od e t e c tβ-actin (the
internal control) by incubating it with mouse antihuman β-
actin antibody (Gene, Hong Kong, China). Bands observed
on the photography ﬁlms were analyzed by automatic image
analysis. The integrated optical density of each protein band
was normalized to that of the corresponding β-actin band
from the same sample.
2.5. Rat Retinal Capillary Endothelial Cell (RRCEC) Culture.
RRCECs cultured in vitro were prepared as previously
described [24]. Two-month-old male Sprague Dawley rats
weighing 150–200g (n = 60) were obtained from the animal
center of Huazhong University of Science and Technology.
After anesthesia, the eyes were removed, and the retinas
harvested and homogenized by two gentle up-and-down
strokes in a 15mL homogenizer (Dounce; Bellco Glass,
Vineland, NJ). The homogenate was ﬁltered through an
88μm sieve. The retentate was digested in 0.066% collage-
nase for 45min at 37◦C. The homogenate was centrifuged
(1000×g for 10min), and the pellet was resuspended in
endothelial basal growth medium (Invitrogen-Gibco, Grand
Island, NY), supplemented with 20% fetal bovine serum,
50U/mL endothelial cell growth factor (Sigma-Aldrich, St.
Louis, Mo), and 1% insulin-transferrin-selenium. RRCECs
were cultured in ﬁbronectin-coated dishes and incubated at
37◦C in a humidiﬁed atmosphere containing 5% CO2.
Cultured endothelial cells were characterized by evaluat-
ing expression of factor VIII antigen (von Willebrand factor)
and determining unchanged morphology under cultureExperimental Diabetes Research 3
Table 1: Q-PCR arrays showed that the expression of the ER stress factor had signiﬁcant diﬀerences in the ﬁrst and the third month in
diabetic rat retina: The ER stress factor of diﬀerential gene expression in the ﬁrst month.
Symbol Gene name The average ratio of gene expression t-test
DR control P value
CCT4 Cctd 9.50E −02 5.90E −02 0.0134
DNAJB9 Erdj4 4.10E −02 6.20E −02 0.0125
DNAJC3 P58IPK 1.70E −02 3.00E −02 0.0173
Casp12 Casp12 3.20E −04 1.30E −03 0.002
ERP44 Pdia10 2.10E −02 2.50E −02 0.0337
GANAB GluII 8.10E −02 1.40E −01 0.045
HERPUD1 Herp 1.50E −01 2.60E −01 0.0006
HSPA1L Hsp70-3 6.30E −04 1.00E −03 0.0183
HSPA2 Hspt70 7.30E −03 1.30E −02 0.0183
MAPK8 JNK 1.10E −02 2.00E −02 0.0391
NUCB1 NUC 2.80E −02 5.60E −02 0.0289
OS9 OS-9 9.10E −02 1.50E −01 0.0272
SELS AD-015 7.00E −02 9.30E −02 0.0486
Table 2: Q-PCR arrays showed that the expression of the ER stress factor had signiﬁcant diﬀerences in the ﬁrst and the third month in
diabetic rat retina: The ER stress factor of diﬀerential gene expression in the third month.
Symbol Gene name The average ratio of gene expression t-test
DR control P value
ATF4 CREB-2 8.80E −01 1.60E +00 0.0178
DNAJB9 Erdj4 4.10E −02 5.40E − 02 0.0106
ERO1L Ero1 9.50E −03 1.20E − 02 0.0492
TRB3 Trib3 5.80E −03 6.10E − 02 0.0024
HERPUD1 Herp 7.20E −02 2.80E − 01 0.0008
HTRA2 PARK13 2.20E −02 4.00E − 02 0.0064
PPIA CYPA 4.30E −01 6.50E − 01 0.0238
SREBF1 SREBP1 2.10E −02 2.80E − 02 0.0187
SYVN1/Hrd1 HRD1 7.90E −02 1.20E − 01 0.0067
UFD1L UFD1 1.60E −01 8.00E − 02 0.0463
UGCGL1 HUGT1 9.80E −03 2.10E − 02 0.0833
USP14 TGT 7.30E −02 4.80E − 02 0.0405
Table 3: Q-PCR arrays showed that the expression of the ER stress factor had signiﬁcant diﬀerences in the ﬁrst and the third month in
diabetic rat retina: the ER stress factor of signiﬁcant diﬀerences belongs to diﬀerent ER stress signaling pathways.
Signaling pathway First month Third month
Unfolded protein binding Cctd, ERdj4, Hspt70-3 ERdj4, OMI/PARK13, CYPA, HUGT1
ER protein folding quality control GluII, PDIA10 HUGT1
Regulation of cholesterol Metabolism —S R E B P 1
Regulation of translation ——
ERAD Herp, NUC, Os9, ADO15 Herp, OMI/PARK13, Hrd1
Ubiquitination Herp Herp, UfD1, TGT
Transcription factors — ATF4, SREBP1
Protein folding Cctd, ERdj4, APG-1, PDIA10 ERdj4, Ero1l, CYPA
Protein disulﬁde isomerization PDIA10 SREBP1
Heat shock proteins ERdj4, P58IPK, Hspt70-3 ERdj4
Apoptosis JNK/JNK1, Casp12 OMI/PARK13, NIPK/Trib34 Experimental Diabetes Research
Table 4: Q-PCR array gene table. We selected 89 ER stress-related factors, and other 6 genes as a quality control a total; of 96 genes were
detected in Q-PCR arrays.
A01Rn.107561 XM 341644 AMFR Autocrine motility factor receptor AMFR
A02Rn.161941 NM 001108183 ARMET Arginine rich, mutated in early-stage tumors ARMET
A03 Rn.2423 NM 024403 ATF4 Activating transcription factor 4
(tax-responsive enhancer element B67) CREB-2/CREB2
A04Rn.222130 NM 001107196 ATF6 Activating transcription factor 6 ATF6A
A05 Rn.18179 NM 001002809 ATF6B Activating transcription factor 6 beta CREB-RP/CREBL1
A06 Rn.42932 NM 021702 ATXN3 Ataxin 3 AT3/ATX3
A07 Rn.10668 NM 017059 BAX BCL2-associated X protein BCL2L4
A08 Rn.974 NM 022399 CALR Calreticulin CRT/RO
A09 Rn.1762 NM 172008.2 CANX Calnexin CNX/IP90
A10 Rn.97889 NM 182814.2 CCT4 Chaperonin containing TCP1, subunit 4
(delta) CCT-DELTA/Cctd
A11 Rn.62267 NM 001106603.1 CCT7 Chaperonin containing TCP1, subunit 7
(eta) CCT-ETA/Ccth
A12 Rn.6479 NM 024125.4 CEBPB CCAAT/enhancer binding protein (C/EBP),
beta C/EBP-beta
B01 Rn.104043 NM 001013092.1 CREB3 CAMP responsive element binding protein 3 LUMAN/LZIP
B02 Rn.20059 NM 001012115.1 CREB3L3 CAMP responsive element binding protein
3-like 3 CREB-H/CREBH
B03 Rn.11183 NM 001109986 DDIT3 DNA-damage-inducible transcript 3 CEBPZ/CHOP
B04 Rn.110990 NM 001014202.1 DERL1 Der1-like domain family, member 1 DER-1/DER1
B05 Rn.11209 NM 031627 CHOP Rattus norvegicus nuclear receptor
subfamily 1, group H, member 3 LXRalpha/Nr1h3
B06 Rn.40780 NM 001109541 DNAJB2 DnaJ (Hsp40) homolog, subfamily B,
member 2 HSJ1/HSPF3
B07 Rn.29778 NM 012699 DNAJB9 DnaJ (Hsp40) homolog, subfamily B,
member 9 DKFZp564F1862/ERdj4
B08 Rn.8642 NM 001106486 DNAJC10 DnaJ (Hsp40) homolog, subfamily C,
member 10 DKFZp434J1813/ERdj5
B09 Rn.162234 NM 022232 DNAJC3 DnaJ (Hsp40) homolog, subfamily C,
member 3 HP58/P58
B10 Rn.91398 NM 001013196 DNAJC4 DnaJ (Hsp40) homolog, subfamily C,
member 4 DANJC4/HSPF2
B11 Rn.107459 NM 001033909 Elf2 E74-like factor 2 Elf2
B12 Rn.81078 NM 130422 Casp12 Caspase 12 Casp12
C01Rn.198593 NM 001109339 eIF2A Eukaryotic translation initiation factor 2A,
65kDa CDA02/EIF-2A
C02 Rn.24897 NM 031599 EIF2AK3 Eukaryotic translation initiation factor
2-alpha kinase 3 DKFZp781H1925/HRI
C03 Rn.19198 NM 001037208 CRELD2 cysteine-rich with EGF-like domains 2 Creld2
C04Rn.218563 XM 344959.3 ERN2 Endoplasmic reticulum to nucleus signaling
2 Ern2
C05 Rn.64648 NM 138528 ERO1L ERO1-like (S. cerevisiae) Ero1l
C06 Rn.22325 NM 144755 TRB3 Tribbles homolog 3 NIPK/Trib3
C07 Rn.2459 NM 001008317 ERP44 Thioredoxin domain containing 4
(endoplasmic reticulum) PDIA10/TXNDC4
C08 Rn.57325 NM 138917 FBXO6 F-box protein 6 FBG2/FBS2
C09 Rn.99241 NM 001106334 GANAB Glucosidase, alpha; neutral AB G2AN/GluII
C10 Rn.23744 NM 001145840 GANC Glucosidase, alpha; neutral C MGC138256
C11 Rn.4028 NM 053523 HERPUD1
Homocysteine-inducible, endoplasmic
reticulum stress-inducible, ubiquitin-like
domain member 1
Sup
C12 Rn.1950 NM 212504 HSPA1B Heat shock 70kDa protein 1B HSP70-1B/HSP70-2/Hsp72
D01Rn.187184 NM 212546 HSPA1L heat shock protein 1-like Hsp70-
3/MGC112562/MGC114222Experimental Diabetes Research 5
Table 4: Continued.
D02Rn.211303 NM 021863 HSPA2 Heat shock protein 2 Hspt70/Hst70/MGC93458
D03Rn.163092 NM 153629 HSPA4 Heat shock protein 4 Hsp110/ Hsp70/irp94
D04Rn.144829 NM 001106428 HSPA4L Heat shock protein 4-like APG-1; MGC187594; OSP94
D05 Rn.11088 NM 013083 HSPA5 Heat shock 70kDa protein 5
(glucose-regulated protein, 78kDa) BIP/GRP78
D06 Rn.37805 NM 001011901 HSPH1 Heat shock 105kDa/110kDa protein 1 DKFZp686M05240/HSP105
D07Rn.107325 NM 001106599 HTRA2 HtrA serine peptidase 2 OMI/PARK13
D08Rn.163330 NM 001107321 HTRA4 HtrA serine peptidase 4 FLJ90724
D09 Rn.772 NM 022392 INSIG1 Insulin-induced gene 1 CL-6
D10 Rn.16736 NM 178091 INSIG2 Insulin-induced gene 2 MGC26273
D11 Rn.9911 NM 012806 MAPK10 Mitogen-activated protein kinase 10 JNK3/JNK3A
D12 Rn.4090 XM 001056513 MAPK8 Mitogen-activated protein kinase 8 JNK/JNK1
E01 Rn.9910 NM 017322 MAPK9 Mitogen-activated protein kinase 9 JNK-55/JNK2
E02 Rn.2362 NM 053569 MBTPS1 Membrane-bound transcription factor
peptidase, site 1 PCSK8/S1P
E03 Rn.212224 NM 001035007 MBTPS2 Membrane-bound transcription factor
peptidase, site 2 S2P
E04 Rn.144645 NM 080577 NPLOC4 Nuclear protein localization 4 homolog (S.
cerevisiae) NPL4
E05 Rn.1492 NM 053463 NUCB1 Nucleobindin 1 DKFZp686A15286/NUC
E06 Rn.1579 NM 001007265 OS9 Osteosarcoma ampliﬁed 9, endoplasmic
reticulum associated protein OS-9
E07 Rn.11527 NM 017319 PDIA3 Protein disulﬁde isomerase family A,
member 3 ER60/ERp57
E08 Rn.7627 NM 001109476 PFDN2 Prefoldin subunit 2 PFD2
E09 Rn.3401 NM 001106794 PFDN5 Prefoldin subunit 5 MM-1/MM1
E10 Rn.1463 NM 017101 PPIA Peptidylprolyl isomerase A (cyclophilin A) CYPA/CYPH
E11 Rn.2232 NM 133546 PPP1R15A Protein phosphatase 1, regulatory
(inhibitor) subunit 15A GADD34
E12 Rn.104417 NM 001106806 PRKCSH Protein kinase C substrate 80K-H AGE-R2/G19P1
F01 Rn.209127 NM 001127545 RNF139 Ring ﬁnger protein 139 HRCA1/RCA1
F02 Rn.209127 NM 006913 RNF5 Ring ﬁnger protein 5 RING5/RMA1
F03 Rn.4224 NM 013067 RPN1 Ribophorin I DKFZp686B16177/OST1
F04 Rn.99548 NM 001100966 SCAP SREBF chaperone KIAA0199
F05 Rn.98327 NM 001034129 SEC62 SEC62 homolog (S. cerevisiae) Dtrp1/HTP1
F06 Rn.24233 NM 001107637 SEC63 SEC63 homolog (S. cerevisiae) ERdj2/PRO2507
F07 Rn.20802 NM 177933 SEL1L Sel-1 suppressor of lin-12-like (C. elegans) IBD2/PRO1063
F08 Rn.4197 NM 173120 SELS Selenoprotein S AD-015/ADO15
F09 Rn.2119 NM 030835 SERP1 Stress-associated endoplasmic reticulum
protein 1 RAMP4
F10 Rn.103851 NM 199376 SIL1 SIL1 homolog, endoplasmic reticulum
chaperone (S. cerevisiae) BAP/MSS
F11 Rn.221929 XM 001075680 SREBF1 Sterol regulatory element binding
transcription factor 1 SREBP-1c/SREBP1
F12 Rn.41063 NM 001033694 SREBF2 Sterol regulatory element binding
transcription factor 2 SREBP2/bHLHd2
G01Rn.162486 NM 001100739 SYVN1 Synovial apoptosis inhibitor 1, synoviolin HRD1
G02 Rn.7102 NM 012670 TCP1 T-complex 1 CCT-alpha/CCT1
G03 Rn.20041 NM 153303 TOR1A Torsin family 1, member A (torsin A) DQ2/DYT1
G04Rn.139603 NM 001106380 UBE2G2 Ubiquitin-conjugating enzyme E2G 2
(UBC7 homolog, yeast) UBC7
G05Rn.106299 NM 001007655 UBE2J2 Ubiquitin-conjugating enzyme E2, J2
(UBC6 homolog, yeast) NCUBE2/PRO2121
G06 Rn.2022 NM 001012025 UBXN4 UBX domain protein 4 UBXD2/UBXDC1
G07 Rn.11946 NM 053418 UFD1L Ubiquitin fusion degradation 1-like (yeast) UFD16 Experimental Diabetes Research
Table 4: Continued.
G08Rn.162227 NM 133596 UGCGL1 UDP-glucose ceramide
glucosyltransferase-like 1 HUGT1
G09Rn.107678 NM 019381 BI-1 Transmembrane BAX inhibitor motif
containing 6 Tmbim6
G10 Rn.11790 NM 001008301 USP14 Ubiquitin-speciﬁc peptidase 14
(tRNA-guanine transglycosylase) TGT
G11 Rn.98891 NM 053864 VCP Valosin-containing protein IBMPFD/TERA
G12Rn.101044 NM 001004210 XBP1 X-box binding protein 1 TREB5/XBP2
H01 Rn.973 NM 001007604 Rplp1 Ribosomal protein, large, P1 MGC72935
H02 Rn.47 NM 012583 Hprt Hypoxanthine guanine phosphoribosyl
transferase Hgprtase/Hprt1
H03 Rn.92211 NM 173340 Rpl13a Ribosomal protein L13A Rpl13a
H04Rn.107896 NM 017025 Ldha Lactate dehydrogenase A Ldh1
H05 Rn.94978 NM 031144 Actb Actin, beta Actx
H06 N/A U26919 RGDC Rat genomic DNA contamination RGDC
H07 N/A SA 00104 RTC Reverse Transcription Control RTC
H08 N/A SA 00104 RTC Reverse transcription control RTC
H09 N/A SA 00104 RTC Reverse transcription control RTC
H10 N/A SA 00103 PPC Positive PCR control PPC
H11 N/A SA 00103 PPC Positive PCR control PPC
H12 N/A SA 00103 PPC Positive PCR control PPC
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Figure 1: Assessment of the expression of ER stress-related factors in diabetic retinas in the ﬁrst and third months after the development
of diabetes by Q-PCR arrays. (a) the histogram of the expression of diﬀerent genes in 11 signaling pathways related to ER stress after the
ﬁrst month; (b) the histogram of the expression of diﬀerent genes in 11 signaling pathways related to ER stress after the third month.
Unfolded Protein Binding: UPB, ER Protein Folding Quality Control: ERPFQC, Regulation of Cholesterol Metabolism: RCM, ER-associated
degradation: ERAD, Ubiquitination: Ub, Transcription Factors: TF, Protein Folding: PF, Protein Disulﬁde Isomerization: PDI, Heat Shock
Proteins: HSP, Apoptosis: Ap◦.
conditions by light microscopy. The expression of acetyl-
LDL (Ac-LDL) receptors in endothelial cells was measured
by adding ﬂuorescence-labeled AC-LDL (Biomedical Tech-
nologies, Palatine, Il). Only cells from passages 3 to 7 were
used in the experiments.
2.6. Cell Immunoﬂuorescence. The RRCECs were grown in
24-well plates in human endothelial serum-free material
basal growth medium containing 8.3mM glucose. Upon
attaining 80%, conﬂuency cells were treated with medium
containing 25mM glucose for 2d. Cells were then ﬁxedExperimental Diabetes Research 7
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Figure 2: Western blot and immunoﬂuorescence detected the expression of HERP and HRD1 in the ﬁrst month after the development of
diabetes: (a) Western blot detection of the expression of HERP and HRD1 in the ﬁrst month. The expression of HERP in the diabetic group
was less than that of the control group (P = 0.004); Hrd1 expression was similar in both groups (P = 0.338). (b) Immunoﬂuorescence
detection of the expression of HERP and HRD1 in the ﬁrst month. The expression of HERP in the diabetic group was less than that of the
control group (P = 0.008) Hrd1 expression was similar in both groups (P = 0.572).
with 4% formaldehyde for 15min and permeabilized in
0.1% Triton X-100 for 10min. Cells were incubated with
primary antibody at 4◦C overnight followed by secondary
antibody for one hour. The slides were visualized and
photographed under a ﬂuorescence microscope (Olympus,
Hamburg, Germany).
2.7.StatisticalAnalysis. Normallydistributeddatawerecom-
pared using Student’s independent samples t-test or one-way
ANOVA where appropriate. When a signiﬁcant diﬀerence
was detected between groups, multiple comparisons of
means were performed using the Bonferroni procedure, with
type-I errorrate ata maximumof 0.017 (0.05/3) adjustment.
Statistical analyses were performed using Statistical Package
for the Social Sciences (SPSS) 15.0 software (SPSS, Chicago,
IL). Data were presented as the mean ± standard deviation
(SD). A probability (P)v a l u e< 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Q-PCR Arrays. We detected 89 ER stress-related genes
and found that the mRNA levels of 13 genes in the diabetic
rats changed signiﬁcantly during the ﬁrst month (Table 1).
We found that in the third month the levels of expression
of 12 genes were changed signiﬁcantly in these diabetic
rats (Table 2). The changes in the expression levels of genes
corresponded to 8 and 10 categories of signal pathways in the
ﬁrst and third months, respectively (Figure 1 and Table 3).
The mRNA expressions of Erdj4 and HERP were lower both
in the ﬁrst and third months.8 Experimental Diabetes Research
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Figure 3: Western blot and immunoﬂuorescence detected the expression of HERP and Hrd1 in the third month after the development of
diabetes: (a) Western blot detection of the expression of HERP and Hrd1 in the third month. The expression of HERP and Hrd1in the
diabetic group was less than that of the control group (P = 0.012 and P = 0.001, resp.). (b) immunoﬂuorescence detection of the expression
of HERP and HRD1 in the third month. The expression of HERP and Hrd1 in the diabetic group was less than that of the control group
(P = 0.007 and P = 0.003, resp.).
3.2. Expression of HERP and HRD1 in the Retinas of Diabetic
Rats. We detected HERP and Hrd1 protein expression
levels in the retinas of diabetic rats by Western blot and
immunoﬂuorescence in the ﬁrst and the third months of
diabetes development. The Western blot suggested that the
HERP expression decreased signiﬁcantly in the ﬁrst month
(P = 0.004) and third month (P = 0.012) compared with
the nondiabetic control group. No signiﬁcant change in the
expression level of Hrd1 was observed in the ﬁrst month
(P = 0.338), while it decreased signiﬁcantly in the third
month compared with the control group (P = 0.001; Figures
2 and 3).
The results of immunoﬂuorescence were consistent with
the Western blot. The protein level of HERP decreased
signiﬁcantly at both the ﬁrst and third months (P = 0.008
and 0.007, resp.; Figures 2 and 3). There was no signiﬁcant
change in the expression of retinal HRD1 in the ﬁrst month,
whileitdecreasedsigniﬁcantlyinthethirdmonth(P = 0.572
and 0.003, resp. Figures 2 and 3).
3.3. Expression of HERP and HRD1 in RRCECs in the Presence
of High-Glucose Concentration. The expression levels of
HERP and HRD1 in RRCECs in vitro in the presence of high
glucoseconcentrationweredecreasedsigniﬁcantlycompared
to the control group (P = 0.013 and 0.024, resp.; Figure 4).
4. Discussion
The STZ-induced rat diabetes model is anestablished animal
model for studying DR. Although we did not verify the
development of DR in this study, our previous studies and
the publication from another group have demonstrated that
DR develops within one month of STZ-induced diabetesExperimental Diabetes Research 9
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Figure 4: Immunoﬂuorescence detection of the expression of HERP and HRD1 in RRCECs. The expression of HERP in the high glucose
group was decreased compared to the control group, P = 0.013. The expression of HRD1 in the high glucose group was also decreased
compared to the control group, P = 0.024.
[13, 22, 23]. Our results indicate that of 89 ER stress genes,
the expression of 12 genes in the retinas of diabetic rats was
downregulated by the third month of diabetes development,
andtheexpressionofCCT4increasedwithintheﬁrstmonth.
We did not observe any change in the expression of AFT4 or
GFP78 at either time point in our study, which is consistent
with our earlier results [13].
The expression of genes belonging to 8 diﬀerent cate-
goriesofERstressfactorswasalteredintheﬁrstmonth,while
those of 10 categories were changed by the third month,
suggesting that with increasing time more categories of ER
stress factors were involved in the pathogenic process of DR.
The expression of a number of related factors of the ERAD
signaling pathways was downregulated, indicating that the
ERAD signaling pathway may play an important role in DR.
The ERAD system is an important pathway of protein degra-
dation in the ER [25, 26] and plays important physiological
roles. The ER is the location of protein synthesis, and secre-
tion[27,28]andhasstrictqualitycontrolmechanismswhich
allow secretion of correctly folded protein into the cyto-
plasm. The wrongly folded protein will be degraded through
ERAD. ERAD therefore is a quality control system of the ER.
Recent studies found that HRD1 plays a central role in
the ERAD-luminal pathway [29] and that HERP coordinates
and regulates HRD1-mediated ubiquitylation [28], so we
selected HRD1 and HERP from the ERAD pathway for
further study. HERP expression was downregulated sig-
niﬁcantly in the retinas of diabetic rats in the ﬁrst and
third months. HERP is a membrane-bound, ubiquitin-like
protein that is located in the ER. It forms a complex with
ubiquitinatedproteinsandwiththe26Sproteasome[30–33].
HERP functions to degrade wrongly folded nonglycosylated
proteins by forming a protein-enzyme complex with Derlin-
1, HRD1, and p97 [34]. In our study, HRD1 expression in
the retinas of diabetic rats remained unchanged in the ﬁrst
month, while it decreased in the third month. HRD1 is an E3
ubiquitinligaseandakeyfactorofERAD[35–37].ERADhas
threepathwaysinyeast[38]:ERAD-L,ERAD-M,andERAD-
C. Both ERAD-L and ERAD-M are the key enzymes of
HRD1. In the mammalian ERAD, HRD1 plays a very broad
role in the ubiquitination process of abnormal proteins in
the ER. The ubiquitin ligase HRD1 is mainly involved in the
degradation of glycosylation proteins [39–41].
The decreased expression of HERP and HRD1 at both
the mRNA and protein levels could lead to a decrease in
functionofERAD’sabilitytoremovewronglyfoldedproteins
inthecell.MisfoldedproteinaccumulationintheERinduces
ER stress and activates signaling pathways, including PERK,10 Experimental Diabetes Research
ATF6, and IRE1 [15]. Persistent ER stress leads to cell death
and induction of inﬂammation [42–45]. An inﬂammatory
milieu is instrumental in breaking down the blood-retinal
barrier in DR [46, 47].
In conclusion, we have shown by in vivo and in vitro
experiments that an elevated concentration of glucose leads
to downregulation of the ERAD signaling pathway. Such
downregulation may result in local inﬂammation and DR.
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